Agios to Present Clinical Data from its IDH Program at ASCO
May 15 2019 - 4:05PM
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of
cellular metabolism to treat cancer and rare genetic diseases,
today announced that data from its isocitrate dehydrogenase (IDH)
programs will be presented at the American Society of Clinical
Oncology (ASCO) Annual Meeting being held May 31-June 4, 2019 in
Chicago.
The accepted abstracts are listed below and are available online
on the ASCO conference website: http://abstracts.asco.org/.
Oral Presentation:
Title: A phase 1, open label, perioperative
study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade
glioma: Results from cohort 1Date & Time:
Monday, June 3, 2019 from 2:15-2:27 p.m. CTOral Abstract
Session: Central Nervous System
TumorsAbstract: 2003Location:
S102Presenter: Ingo K. Mellinghoff, M.D., Memorial
Sloan Kettering Cancer Center
Poster Presentations:
Title: Ivosidenib (IVO; AG-120) in IDH1-mutant
newly diagnosed acute myeloid leukemia (ND AML): Updated results
from a phase 1 studyPoster Session Date &
Time: Monday, June 3, 2019 from 8:00-11:00 a.m.
CTPoster Session: Hematologic Malignancies –
Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract: 7028Poster Board:
403Poster Location: Hall AAuthor:
Gail J. Roboz, M.D., Weill Medical College of Cornell
University
Title: Mutant IDH1 inhibitor ivosidenib (IVO;
AG-120) in combination with azacitidine (AZA) for newly diagnosed
acute myeloid leukemia (ND AML)Poster Session Date &
Time: Monday, June 3, 2019 from 1:15-4:15 p.m.
CTPoster Session: Hematologic Malignancies –
Leukemia, Myelodysplastic Syndromes, and
AllotransplantAbstract: 7011Poster
Board: 386Poster Location: Hall
AAuthor: Courtney D. DiNardo, M.D., University of
Texas MD Anderson Cancer Center
About AgiosAgios is focused on discovering and
developing novel investigational medicines to treat cancer and rare
genetic diseases through scientific leadership in the field of
cellular metabolism and adjacent areas of biology. In addition to
an active research and discovery pipeline across both therapeutic
areas, Agios has two approved oncology precision medicines and
multiple first-in-class investigational therapies in clinical
and/or preclinical development. All Agios programs focus on
genetically identified patient populations, leveraging our
knowledge of metabolism, biology and genomics. For more
information, please visit the company's website at
www.agios.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include those
regarding the potential benefits of Agios' products and product
candidates, including TIBSOVO® (ivosidenib) and vorasidenib
(AG-881); its plans regarding future data presentations; and the
potential benefit of its strategic plans and focus. The words
“anticipate,” “expect,” “intend,” “potential,” “upcoming,” and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Such statements are subject to numerous
important factors, risks and uncertainties that may cause actual
events or results to differ materially from Agios' current
expectations and beliefs. For example, there can be no guarantee
that any product candidate Agios or its collaborators are
developing will successfully commence or complete necessary
preclinical and clinical development phases, or that development of
any of Agios' product candidates will successfully continue.
Moreover, there can be no guarantee that the two approved oncology
precision medicines being commercialized by Agios and/or its
collaborators will receive commercial acceptance. There can be no
guarantee that any positive developments in Agios' business will
result in stock price appreciation. Management's expectations and,
therefore, any forward-looking statements in this press release
could also be affected by risks and uncertainties relating to a
number of other important factors, including: Agios' results of
clinical trials and preclinical studies, including subsequent
analysis of existing data and new data received from ongoing and
future studies; the content and timing of decisions made by the
U.S. FDA and other regulatory authorities,
investigational review boards at clinical trial sites and
publication review bodies; Agios' ability to obtain and maintain
requisite regulatory approvals and to enroll patients in its
planned clinical trials; unplanned cash requirements and
expenditures; competitive factors; Agios' ability to obtain,
maintain and enforce patent and other intellectual property
protection for any product candidates it is developing; Agios'
ability to maintain key collaborations; and general economic and
market conditions. These and other risks are described in greater
detail under the caption "Risk Factors" included in Agios’ public
filings with the Securities and Exchange Commission. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Agios expressly disclaims any
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by
law.
Contacts
Investor & Media ContactHolly Manning,
617-844-6630Associate Director, Investor
RelationsHolly.Manning@agios.com
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Sep 2023 to Sep 2024